Form 4: Director Erez Kalir Receives Stock Options in Vor Biopharma

Director Erez Kalir was granted 57,162 stock options in Vor Biopharma Inc. as part of a standard equity compensation arrangement.

Summary

• Director Erez Kalir acquired 57,162 stock options in Vor Biopharma Inc. (VOR).
• The options have an exercise price of $14.09 per share.
• The grant date for the transaction was June 11, 2026.
• The options are set to expire on June 10, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no immediate impact on company fundamentals.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of these options.

Risks

• The value of the options is dependent on the future market performance of VOR common stock.
• Vesting is contingent upon the director's continued service to the company.

Future Outlook

The options vest in 36 equal monthly installments starting July 11, 2026, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure leadership remains incentivized toward long-term clinical and commercial milestones.

Comparison to Industry Standards

• The use of monthly vesting schedules over a three-year period is consistent with standard equity compensation practices for board members in mid-cap biotech firms.

Stakeholder Impact

• Minor potential dilution for existing shareholders if options are exercised in the future.

Next Steps

• Commencement of monthly vesting schedule on July 11, 2026.

Key Dates

Keywords

Vor Biopharma, VOR, SEC Form 4, Insider Trading, Stock Options, Director Compensation